Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children’s Oncology Group

PURPOSE: Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine. AAML1421 sought to determine the recommended phase II dose (RP2D) of CPX-351 and the response rate after...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Cooper, Todd M., Absalon, Michael J., Alonzo, Todd A., Gerbing, Robert B., Leger, Kasey J., Hirsch, Betsy A., Pollard, Jessica, Razzouk, Bassem I., Aplenc, Richard, Kolb, E. Anders
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2020
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325367/
https://ncbi.nlm.nih.gov/pubmed/32401633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.03306
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires